| Back to Back Issues Page |
 |
|
Five Year Outcomes Of The Comparison of AMD Treatments Trials (CATT) May 18, 2016 |
Hello Five Year Outcomes Of The Comparison of AMD Treatments Trials (CATT)Preserving one's vision and perhaps even improving vision loss from macular degeneration is the treatment goal of regular eye injections. When patients are told of their need to start these frequent injections, their reactions to this invasive eye procedure range from fear and dread to acceptance that the treatments are indeed worth the inconvenience, cost and discomfort.
This class of drugs known as anti-VEGF targets blood vessels in the retina and more specifically targets vascular endothelial growth factor (VEGF). VEGF is secreted by cells that are oxygen deprived and stimulates the growth of these abnormal blood vessels. Healthy adults secrete very low levels of VEGF, while those who have health conditions such as cancer or age related macular degeneration secrete high levels of this protein. Anti-VEGF inhibits the growth of new, abnormal and leaking blood vessels.
Perhaps knowing that regular injections of anti-VEGF drugs can be sight preserving and that the alternative of no treatment may indeed jeopardize one's vision may bring some relief and comfort to patients.
Find out what the Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration revealed regarding vision preservation.
Anti-VEGF Therapy - Visual Acuity Outcomes Leslie Degner, RN, BSN Better Health for Better Vision |
| Back to Back Issues Page |
